-+ 0.00%
-+ 0.00%
-+ 0.00%
3 Medicare Home Health Stocks That Could Gain From The $90 Part B Payment
Share
Listen to the news

Medicare is about to send roughly 20.8 million Part B beneficiaries a one time $90 payment, and that small check could ripple through home health and durable medical equipment stocks in ways many investors overlook. A targeted cash boost to seniors can shift how care is used at home and who gets paid for it. This piece unpacks the news and explores three stocks that appear positioned to benefit from this policy spark.

The stocks covered below are just a small sample of the Medicare exposed home health and DME universe, and the full screen surfaced 10 more companies with equally compelling narratives that are not discussed here. If you want to identify potential high conviction ideas quickly, head straight into the U.S. Medicare-Focused Home Health & Durable Medical Equipment Providers screener.

AdaptHealth (AHCO)

AdaptHealth is one of the clearest plays on the Medicare home health and DME theme, sitting directly where Part B dollars and seniors’ own budgets meet for in home equipment and supplies.

AdaptHealth distributes home medical equipment and supplies to U.S. patients at home across Sleep Health, Respiratory Health and Wellness at Home, generating about US$1.47b, US$728 million and US$571 million respectively, with a market value around US$747 million.

"The convergence of telehealth, remote patient monitoring, and DME, accelerated by AdaptHealth's tech-enabled care model, may help unlock new verticals as chronic disease management increasingly moves into the home, potentially opening recurring revenue streams and influencing multi-year revenue and EBITDA trends relative to current Street models."

What happens to AdaptHealth’s earnings power if one quiet pressure on its Medicare pricing assumptions moves even slightly in the right direction.

That quiet shift starts with understanding the mechanics behind AdaptHealth’s Medicare exposure. This is exactly what the full narrative for AdaptHealth unpacks, including where consensus may be masking upside potential.

NasdaqCM:AHCO Earnings & Revenue History as at Oct 2026
NasdaqCM:AHCO Earnings & Revenue History as at Oct 2026

Pennant Group (PNTG)

Pennant Group plugs directly into the Medicare-focused home health theme through its mix of in home clinical care and senior communities. This gives investors a single business that touches both medical episodes and everyday support for older Americans across a wide regional footprint.

The Pennant Group runs U.S. home health, hospice and senior living operations that fit the Medicare home care and senior setting theme. It generates about US$872 million from Home Health and Hospice Services and US$222 million from Senior Living Services, with a market cap near US$1.4b.

"While the aging population and accelerating preference for home-based care should create substantial long-term demand for Pennant's services, the company's earnings outlook remains clouded by looming Medicare reimbursement cuts and heightened regulatory risk, which could compress net margins and limit the ability to fully capture this secular growth."

What happens if one quiet policy shift tilts reimbursement just slightly in Pennant Group’s favor at the same time as demand keeps building?

That kind of quiet shift is exactly what the full narrative for Pennant Group lays out, including how Medicare risk, home health momentum and senior housing trends may be decoupling.

NasdaqGS:PNTG Revenue & Expenses Breakdown as at Oct 2026
NasdaqGS:PNTG Revenue & Expenses Breakdown as at Oct 2026

BrightSpring Health Services (BTSG)

BrightSpring Health Services ties directly into the home health theme of this screener, since it delivers care and medication support where many Medicare patients increasingly want to be, at home or in their communities, rather than in hospitals or large facilities.

BrightSpring Health Services runs a U.S. home and community-based care platform that leans heavily on pharmacy services, with Pharmacy Solutions generating about US$12.7b and Provider Services about US$1.7b in revenue, giving the business a market value close to US$12.6b.

"Patients are not “customers” in the retail sense; they are clinically managed cases. Once a patient enters an infusion or specialty pharmacy program, switching providers is rare because treatment continuity is medically sensitive and logistics (cold chain, dosing schedules) are specialized."

The real question is what happens to BrightSpring’s margins and cash generation if one quiet policy or funding shift nudges more Medicare care into these sticky home-based programs.

That kind of subtle policy nudge is exactly what the full narrative for BrightSpring Health Services unpacks, including how BrightSpring could turn Medicare flow into accelerating long term cash strength.

NasdaqGS:BTSG Revenue & Expenses Breakdown as at Oct 2026
NasdaqGS:BTSG Revenue & Expenses Breakdown as at Oct 2026

Seeking Alternatives Before Momentum Flies

Fresh ideas do not stay quiet for long. Once momentum hits, entry points can move quickly and spreads can widen. Scan these under the radar lists now to look for opportunities earlier in the cycle.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending